|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1997-10-2
|
|
pubmed:abstractText |
We used liposomal amphotericin B as first-choice treatment of visceral leishmaniasis in 106 immunocompetent children who acquired the infection in a temperate region of southern Europe (Italy) where Leishmania infantum visceral leishmaniasis is endemic. The aim of the study was to identify the minimum total dose of liposomal amphotericin B needed to cure the infection in children and reduce the period of hospitalization. We conclude that the optimal regimen in immunocompetent children with L. infantum visceral leishmaniasis to be a total dose of 18 mg/kg of liposomal amphotericin B (3 mg/kg per day for 5 days, followed by 3 mg/kg administered as an outpatient regimen on day 10).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0022-3476
|
|
pubmed:author |
pubmed-author:BrycesonA DAD,
pubmed-author:CascioAA,
pubmed-author:CastagnolaEE,
pubmed-author:DavidsonR NRN,
pubmed-author:GiacchinoRR,
pubmed-author:GradoniLL,
pubmed-author:GramicciaMM,
pubmed-author:Pettoello-MantovaniMM,
pubmed-author:RaimondoLL,
pubmed-author:ScottiSS,
pubmed-author:TassoLL,
pubmed-author:di MartinoLL
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
131
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
271-7
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9290615-Adolescent,
pubmed-meshheading:9290615-Ambulatory Care,
pubmed-meshheading:9290615-Amphotericin B,
pubmed-meshheading:9290615-Animals,
pubmed-meshheading:9290615-Antiprotozoal Agents,
pubmed-meshheading:9290615-Bone Marrow,
pubmed-meshheading:9290615-Child,
pubmed-meshheading:9290615-Child, Preschool,
pubmed-meshheading:9290615-Drug Administration Schedule,
pubmed-meshheading:9290615-Drug Carriers,
pubmed-meshheading:9290615-Electrophoresis,
pubmed-meshheading:9290615-Endemic Diseases,
pubmed-meshheading:9290615-Female,
pubmed-meshheading:9290615-Fluorescent Antibody Technique, Indirect,
pubmed-meshheading:9290615-Follow-Up Studies,
pubmed-meshheading:9290615-Hospitalization,
pubmed-meshheading:9290615-Humans,
pubmed-meshheading:9290615-Immunocompetence,
pubmed-meshheading:9290615-Infant,
pubmed-meshheading:9290615-Isoenzymes,
pubmed-meshheading:9290615-Italy,
pubmed-meshheading:9290615-Leishmania infantum,
pubmed-meshheading:9290615-Leishmaniasis, Visceral,
pubmed-meshheading:9290615-Length of Stay,
pubmed-meshheading:9290615-Liposomes,
pubmed-meshheading:9290615-Male
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Treatment of visceral leishmaniasis in children with liposomal amphotericin B.
|
|
pubmed:affiliation |
Department of Pediatrics, Institute Giannina Gashni, Genoa, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
